David R. R Borchelt

Dr. David R. R Borchelt

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2014 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
JAJacob I. Ayers
Jacob I. Ayers
SFSusan Fromholt
Susan Fromholt
MKMorgan Koch
Morgan Koch
ADAdam DeBosier
Adam DeBosier
BMBen McMahon
Ben McMahon
DBDavid R. R Borchelt
David R. R Borchelt

1 February 2018 in Biological Psychiatry
Verified
Journal Article
Closed access
JAJacob I. Ayers
Jacob I. Ayers
BGBenoit I. Giasson
Benoit I. Giasson
DBDavid R. R Borchelt
David R. R Borchelt

24 January 2022 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
KSKim Staats
Kim Staats
DBDavid R. R Borchelt
David R. R Borchelt
MTMariadeLourdes Tansey
MariadeLourdes Tansey
JWJames Wymer
James Wymer
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different types of biomarkers in diagnosis and clinical trials can assist in determining target engagement of a drug, in distinguishing between ALS and other diseases, and in predicting disease progression rate, drug responsiveness, or an adverse event. Ideally, among other characteristics, a biomarker in ALS correlates highly with a disease process in the central nervous system or with disease progression and is conveniently obtained in a peripheral tissue. Here, we describe the state of biomarkers of inflammation in ALS by focusing on peripherally detectable and cellular responses from blood cells, and provide new (combinatorial) directions for exploration that are now feasible due to technological advancements.

5 December 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
BMBrenda D. Moore
Brenda D. Moore
JMJason Martin
Jason Martin
LMLorena de Mena
Lorena de Mena
JSJonatan Sanchez
Jonatan Sanchez
PCPedro E. Cruz
Pedro E. Cruz
TGTodd E. Golde
Todd E. Golde
Processing of amyloid-β (Aβ) precursor protein (APP) by γ-secretase produces multiple species of Aβ: Aβ40, short Aβ peptides (Aβ37–39), and longer Aβ peptides (Aβ42–43). γ-Secretase modulators, a class of Alzheimer’s disease therapeutics, reduce production of the pathogenic Aβ42 but increase the relative abundance of short Aβ peptides. To evaluate the pathological relevance of these peptides, we expressed Aβ36–40 and Aβ42–43 in Drosophila melanogaster to evaluate inherent toxicity and potential modulatory effects on Aβ42 toxicity. In contrast to Aβ42, the short Aβ peptides were not toxic and, when coexpressed with Aβ42, were protective in a dose-dependent fashion. In parallel, we explored the effects of recombinant adeno-associated virus–mediated expression of Aβ38 and Aβ40 in mice. When expressed in nontransgenic mice at levels sufficient to drive Aβ42 deposition, Aβ38 and Aβ40 did not deposit or cause behavioral alterations. These studies indicate that treatments that lower Aβ42 by raising the levels of short Aβ peptides could attenuate the toxic effects of Aβ42.

12 May 2013 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
Jungsu KimJungsu Kim
Jungsu Kim
PCParamita Chakrabarty
Paramita Chakrabarty
AHAmanda Hanna
Amanda Hanna
AMAmelia March
Amelia March
DDDennis W Dickson
Dennis W Dickson
CJChristopher Janus
Christopher Janus
Background: Recent research in Alzheimer’s disease (AD) field has been focused on the potential role of the amyloid-β protein that is derived from the transmembrane amyloid precursor protein (APP) in directly mediating cognitive impairment in AD. Transgenic mouse models overexpressing APP develop robust AD-like amyloid pathology in the brain and show various levels of cognitive decline. In the present study, we examined the cognition of the BRI2-Aβ transgenic mouse model in which secreted extracellular Aβ1-40, Aβ1-42 or both Aβ1-40/Aβ1-42 peptides are generated from the BRI-Aβ fusion proteins encoded by the transgenes. BRI2-Aβ mice produce high levels of Aβ peptides and BRI2-Aβ1-42 mice develop amyloid pathology that is similar to the pathology observed in mutant human APP transgenic models. Results: Using established behavioral tests that reveal deficits in APP transgenic models, BRI2-Aβ1-42 mice showed completely intact cognitive performance at ages both pre and post amyloid plaque formation. BRI2-Aβ mice producing Aβ1-40 or both peptides were also cognitively intact. Conclusions: These data indicate that high levels of Aβ1-40 or Aβ1-42, or both produced in the absence of APP overexpression do not reproduce memory deficits observed in APP transgenic mouse models. This outcome is supportive of recent data suggesting that APP processing derivatives or the overexpression of full length APP may contribute to cognitive decline in APP transgenic mouse models. Alternatively, Aβ aggregates may impact cognition by a mechanism that is not fully recapitulated in these BRI2-Aβ mouse models.

25 February 2021 in Glia
Verified
Journal Article
Open access
PDF file
TSTamar Smit
Tamar Smit
NDNatasja A. C. Deshayes
Natasja A. C. Deshayes
DBDavid R. R Borchelt
David R. R Borchelt
WKWillem Kamphuis
Willem Kamphuis
JMJinte Middeldorp
Jinte Middeldorp
Elly HolElly Hol
Elly Hol
Astrocytes regulate synaptic communication and are essential for proper brain functioning. In Alzheimer's disease (AD) astrocytes become reactive, which is characterized by an increased expression of intermediate filament proteins and cellular hypertrophy. Reactive astrocytes are found in close association with amyloid‐beta (Aβ) deposits. Synaptic communication and neuronal network function could be directly modulated by reactive astrocytes, potentially contributing to cognitive decline in AD. In this review, we focus on reactive astrocytes as treatment targets in AD in the APPswePS1dE9 AD mouse model, a widely used model to study amyloidosis and gliosis. We first give an overview of the model; that is, how it was generated, which cells express the transgenes, and the effect of its genetic background on Aβ pathology. Subsequently, to determine whether modifying reactive astrocytes in AD could influence pathogenesis and cognition, we review studies using this mouse model in which interventions were directly targeted at reactive astrocytes or had an indirect effect on reactive astrocytes. Overall, studies specifically targeting astrocytes to reduce astrogliosis showed beneficial effects on cognition, which indicates that targeting astrocytes should be included in developing novel therapies for AD.